Title: Gastroenterological and Hepatic Manifestations of Patients with COVID-19, Prevalence, Mortality by Country, and Intensive Care Admission Rate: Systematic Review and Meta-analysis.

Mohammad Shehab MD FRCP(C)¹, Fatema Alrashed PharmD MSc², Sameera Shuaibi MD³, Dhuha Alajmi MD⁴, Alan Barkun MD FRCP(C)⁵.

From:

1. **Consultant gastroenterologist, clinical tutor and lecturer at Kuwaiti board of internal medicine, Dept. of internal medicine, Mubarak Alkabeer University Hospital, Kuwait.** (study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis)
2. **Clinical pharmacy resident, Dept of pharmacy practice, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.** (acquisition of data; analysis and interpretation of data; drafting of the manuscript)
3. **Medical resident, Kuwait University, Kuwait.** (acquisition of data; drafting of the manuscript).
4. **Medical resident, Kuwait University, Kuwait.** (acquisition of data)
5. **Chairholder, Douglas G. Kinnear Chair in Gastroenterology and Professor of Medicine, Director of Endoscopy and Therapeutic Endoscopy Training Program, Chief Quality Officer, Division of Gastroenterology, McGill University and the McGill University Health Centre.** (critical revision of the manuscript for important intellectual content; statistical analysis; study supervision)

Correspondence:

Mohammad Shehab, MD ABIM FRCP(C)

Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait.

Aljabreya City, Kuwait.

Tel: +(965)99633181

Personal email: dr_mshehab@hotmail.com. Work email: moshehab@moh.gov.kw

Disclosure:

All authors have no financial disclosures to report.

Abstract

Background & Aims

Patient infected with the SARS-COV2 usually report fever and respiratory symptoms. However, multiple gastrointestinal (GI) manifestations such as diarrhea and abdominal pain has been described. The aim of this study was to evaluate the prevalence of GI, liver function test (LFT) abnormalities, and mortality of COVID-19 patients.

Methods

We performed a systematic review and meta-analysis of published studies that included cohort of patients infected with SARS-COV2 from December 1st, 2019 to July 1st, 2020. We collected data from the cohort of patients with COVID-19 by conducting a literature search using PubMed, Embase, Scopus, and Cochrane according to the preferred reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms, LFTs abnormalities and performed subanalyses to investigate the relationship between gastrointestinal symptoms, geographic location, fatality, and ICU admission.

Results

The available data of 17,802 positive patients for SARS-COV2 from 120 studies were included in our analysis. The most frequent manifestations were diarrhea (13.3%, 95% CI 12-16), nausea (9.1%, 95% CI 9-13) and elevated LFTs (23.7%, 95% CI 21- 27). The overall and GI fatality were 7.2% (95% CI 6 -10), and 1% (95% CI 1- 4) respectively. Subgroup analysis showed non statistically significant associations between GI symptoms/LFTs abnormalities and ICU admissions (OR=3.41, 95% CI 0.87 – 13.4). The GI mortality rate was 0.58% in China and 3.5% in the United States (95% CI 2 - 5).

Conclusion

Digestive symptoms and LFTs abnormalities are common in COVID-19 patients. Our subanalysis shows that the presence of gastrointestinal and liver manifestations does not appear to affect mortality, or ICU admission rate. However, the mortality rate was higher in the United States compared to China.

Introduction

In December 2019 China was struck with a new strain of Coronavirus, Novel Coronavirus (2019 nCov). Within a short period of time, it soon spread to a full pandemic.

It was first noticed by the innumerable cases of pneumonia that suddenly surged amongst local inhabitants in the Province of Wuhan. Soon, the virus was detected through sequencing leading to officially being renamed severe acute respiratory syndrome coronavirus 2 (SARS-COV2) by the International Committee on Taxonomy of Viruses [1-2]. The disease caused by Coronavirus (SARS-COV2) was allocated the title of COVID-19 or ‘Coronavirus disease’ [3]. Coronaviruses in general are single stranded RNA viruses falling under the family of Coronaviridae which also include MERS (MERS Cov) and SARS (SARS Cov)[4]. By the end of May, 5,796, 257 cases of COVID-19 have officially been confirmed worldwide and as of July the number of confirmed cases passed the 12 million mark [5].

It has been established that the transmission of Coronavirus (SARS-COV2) occurs from person to person through upper airway tract (droplet infection) or direct contact [6]. The virus can also be detected in saliva, urine, gastrointestinal tract and possibly through airborne spread [7,8]. The spectrum of symptoms attributable to SARS-COV2 include fever, cough, myalgia, fatigue, and to a lesser extent headache. Patients may also be asymptomatic [9-11]. Diarrhea, nausea and vomiting, as well as liver involvement have all been reported in the literature [12,13]. In fact, gastrointestinal involvement is plausible given that angiotensin converting enzyme 2 (ACE2), the major human cellular receptor for the SARS-COV2, is expressed in the gastrointestinal tract as well as liver cells [14]. We thus conducted a systematic review of published gastrointestinal and liver symptoms associated with COVID-19 on the basis of disease severity, age group, and geographical region.

Methods

Search strategy

A systematic review was conducted using Pubmed, Scopus, Cochrane, and Embase databases. Medical literature searches for human studies were performed from December 1st, 2019 up to July 1st, 2020. The key terms used for the literature search were ((“COVID-19” OR “COVID 2019” OR “severe acute respiratory syndrome coronavirus 2” OR “severe acute respiratory syndrome coronavirus 2” OR “2019 nCoV” OR “SARS-COV2” OR “2019nCoV” OR (“severe acute respiratory syndrome coronavirus 2” OR “SARS-COV2” AND GASTROINTESTINAL AND (MANIFESTATIONS OR CLINICAL CHARACTERISTICS) OR (“gastrointestinal tract” OR (“gastrointestinal’ AND “tract”) OR “gastrointestinal tract” OR (“gi” AND “tract”))

OR (“fatality” or “Mortality”). In addition, a manual search of all review articles, editorials and retrieved original studies was also performed. All procedures used in this meta-analysis were consistent with the Preferred Reporting Items for Systematic Reviews and Meta analyses (PRISMA) guidelines and prespecified protocol, which described our method and analysis before data collection was initiated (see supplementary PRISMA check list).

Selection criteria and data extraction

Data were independently abstracted based on our protocol by two investigators (MS and FA) and any discrepancies between the two authors were resolved through discussion. Inclusion and exclusion criteria were defined prior to the literature search. The inclusion criteria were (1) study type: case reports/case series (including chart reviews), prospective/retrospective cohort studies, case control studies, cross sectional studies and randomized controlled trials; (2) patients population: Adults patients with COVID-19; inpatient or outpatient setting and (3) Outcome measured: At least one GI manifestation reported and LFT abnormality, defined as any value above the normal upper limit.

Exclusion criteria were (1) Review, opinion, abstracts from conferences, editorials, commentary articles, review articles and meta analyses; (2) studies without data for retrieval; (3) duplicate studies; (4) Asymptomatic patients with COVID-19; (5) studies that did not report gastrointestinal symptoms.

Data extraction was performed using Microsoft excel. The following data were extracted:

1. Study: author, journal, date, country, number of patients, and study type.
2. Patients characteristics: mean age, ethnicity, gender, and comorbidities.
3. Overall fatality rate and fatality rate by country.
4. Number of patients admitted to the ICU.
5. Gastrointestinal symptoms proportion: abdominal pain, diarrhea, nausea, anorexia, loss of taste, elevated liver enzymes or other nonspecified gastrointestinal symptoms.

Figure 1: Flow diagram for study selection

Risk of bias and certainty of evidence

The Methodical Index for Nonrandomized Studies (MINORS) [15] was used to assess bias risk (see table 2). In addition, risk of bias was assessed based on 4 domains: selection, ascertainment, causality, and reporting. An overall judgment of risk of bias was made based on factors deemed to be most critical for the systematic review (selection criteria, ascertainment of outcome, and followup duration).

Statistical Analysis

Our primary analysis focused on assessing the weighted pooled prevalence of GI symptoms/LFT abnormalities in patients with COVID-19 infection, occurring any time during the course of illness. We also conducted subanalyses that looked at the association between GI symptoms/LFT abnormalities and mortality as well as ICU admission. Categorical variables were described as count (%). Continuous variables were described using mean (SD) if they are normally distributed, median (IQR) if they are not. We pooled the single arm event rates using a random effects method and we measured heterogeneity within our studies using the I^2 statistic. Subanalyses were described and tested using odd ratios and 95% confidence interval to determine statistical significance. Stata 16 was used to calculate odd ratios and their respective 95% CI and create Forest and Box plots.

Sensitivity Analysis

To examine the effect of the quality of studies on our results, we performed a sensitivity analysis on the prevalence of GI symptoms and LFTs abnormalities by excluding low qualities studies. These include case reports, case series and case control studies. We also assessed selected outcomes comparing patients with versus without GI/LFTs abnormalities.

RESULTS

Research selection and quality assessment

Overall, 120 studies (supplementary table. S1) from 2355 potentially relevant citations were included in the analysis (Figure 1). Most of the included studies were single arm only, very few studies included comparator groups. Furthermore, outcome assessors in all 120 studies were not blinded. Both inpatients and outpatients studies were included. The risk of evidence imprecision

was rated as very serious, given that the included studies were all observational studies. Overall, all included studies were rated as having very serious risk of bias because they lacked a control group and had a high risk of confounding and selection bias.

Clinical data

This systematic review included 120 studies [16-136] with a total of 17,801 patients that tested positive for SARS-COV2 and were included in the analysis. The mean patient age was 52.6 (± 14 , 95% CI 48-57.3) and 47.6% of the patients were males. Most patients had several comorbidities, most common being hypertension (23.4%, 95% CI 21-27), diabetes mellites (13.4%, 95% CI, 12-15), and cardiovascular diseases (12.4%, 95% CI, 10-14). GI symptoms included nausea, vomiting, and diarrhea. Heterogeneity statistic I^2 is 94.5%, which signifies a significant heterogeneity among our studies. The most common GI/liver manifestations were elevated liver enzymes and diarrhea (supplementary figure.1). Specifically, GI manifestations of patients infected with SARS-COV2 are diarrhea 13.3% (95% CI 12 - 16), nausea (9.1%, 95% CI 9 - 13) anorexia or loss of appetite (8.3%, 95% CI 8 - 11), vomiting (6.4%, 95% CI 5 - 8), abdominal pain (3%, 95% CI, 3-6), loss of taste (1.3%, 95% CI 1 - 4), and elevated LFTs (23.7%, 95% CI 21 - 27).

Figure 2: Box plots representing the range and outliers of the gastrointestinal and liver manifestations in patients with COVID-19.

Sensitivity Analysis

The sensitivity analysis included 25 studies (supplementary: table S4). The results did not differ from our main analysis. Among the GI manifestations experienced by COVID-19 patients, diarrhea (13.1%, 95% CI, 12- 14), was still the most common symptom, followed by nausea (9.2%, 95% CI 8-11). The percentage of patients experiencing LFTs abnormalities was 24% (95% CI 21 - 26).

Fatality rates and Geographic Variation:

A total of 78 studies reported the incidence of mortality. The overall fatality rate of patients was 7% (95% CI 6 -10), (supplementary: table S5). The subgroup analysis included three studies [19-21] that directly compared mortality rate in patients with and without GI symptoms. In this analysis the number of patients who experienced gastrointestinal symptoms/liver test anomalies and those who did not were 227 and 326, respectively. The results showed that patients with GI manifestations//LFT abnormalities were no more likely to die compared to those who did not with a pooled odd of patients was not statistically significant 1.07 (95% CI 0.58 - 1.97) (figure 3).

Moreover, out of the 78 studies, a total of 25 studies reported mortality in patients with GI/Liver manifestations (see figure 4). A subanalysis of fatality rate in patients with GI symptoms based on their location showed that 27 out 4660 patients (0.58%) in China died (95% CI 0.5, 1.6), whereas 16 out 449 patients (3.5%) in the United States died (95% CI 2 - 5). In addition, 3 studies from Taiwan, Korea, and Japan reported zero fatality (table.1).

Figure 3: Forest Plot for mortality in patients with COVID-19, showing no significant difference in the pooled odds of patients with gastrointestinal symptoms and those without gastrointestinal adverse events.

Figure 4: Funnel plot of the 25 studies that reported mortality of patients with GI symptoms

Table. 1 Mortality by geographic location

ICU admission rate

Only two studies [20,21] reported differences in ICU admissions amongst patients manifesting GI symptoms/LFT abnormalities and patients without. The total number of patients with gastrointestinal problems or LFT abnormalities who were admitted in the ICU were 23 and the number of patients who did not experience gastrointestinal problems or LFT abnormalities and were admitted to the ICU were 156. No statistically significant difference in ICU admission rate was noted between those who experienced GI/LFTs abnormalities and those who did not. The pooled proportion was 3.41 (95% CI, 0.87,13.4). (Figure. 5).

Figure.5: Odds ratio of ICU admissions in patients with COVID-19 amongst patients with and without gastrointestinal symptoms / LFT abnormalities.

Discussion

This meta-analysis of 17,801 COVID-19 patients found that gastrointestinal symptoms are common in patients infected with SARS-COV2. Our study has several strengths. This is one of the more recent meta-analyses that summarizes the rapidly emerging and sometimes confusing literature on COVID-19 on the prevalence of overall and individual gastrointestinal manifestations. The large patient population and comprehensive inclusion of 120 studies allow a more precise estimation of the prevalence of gastrointestinal symptoms and liver test anomalies associated with COVID-19. Subgroup analysis found that no association between the presence of gastrointestinal symptoms/LFT anomalies and mortality; but a trend towards their absence and ICU admission was noted.

Gastrointestinal symptoms including abdominal pain, diarrhea, nausea, vomiting, loss of appetite, loss of taste and elevated liver enzyme are among the presenting symptoms or laboratory abnormalities of SARS-COV2 infection. Diarrhea was the most common gastrointestinal symptom; this is particularly important because previous studies have shown that patients with diarrhea on presentation have a higher stool RNA positivity and viral load than those without [137,138]. One study showed that 44 of 153 patients with COVID-19 tested positive for the virus in the stools [139]. Another study by Xiao et al. showed that among 73 hospitalized COVID-19 patients in China, 39 (53.42%) tested positive for SARS-COV2 RNA in stools [140]. In addition, a report of a COVID-19 patient with positive fecal but negative pharyngeal and sputum viral tests has been described [140]. This may imply that fecal oral route is a possible route of SARS-COV2 transmission.

The possibility of fecal oral transmission of SARS-COV2 emphasizes the importance of frequent and proper hand hygiene. This is important in every clinical setting, but especially in low resource areas with poor sanitation. Intuitively, proper handling of the excreta of COVID-19 patients should still be strongly enforced, and sewage from hospitals should also be properly disinfected. The presence of the virus in the digestive tract also raises the concerns of COVID-19 infection in patients with established gastrointestinal conditions as well as potential fecal

microbiota transplant donors. Nevertheless, the unknown effect of COVID-19 on patients with preexisting gastrointestinal diseases and its influence on treatment and outcome is a cause for concern [140]. These implications warrant further investigation. The American Gastroenterological Association (AGA) and joint society recommend the use of enhanced personal protective equipment, including the use of N95 (or N99) masks instead of surgical masks, for health care workers performing upper or lower GI procedures regardless of COVID19 status [141].

It is believed that the prevalence of gastrointestinal symptoms is underestimated because the majority of studies only reported gastrointestinal symptoms on the day of admission but not throughout the disease course [142]. Furthermore, many earlier studies did not report on other gastrointestinal symptoms except for diarrhea [141,143]. Based on these findings, clinicians must be aware that digestive symptoms, such as diarrhea, may be a presenting feature of COVID-19 that can arise before respiratory symptoms, and on rare occasions may be the only presenting manifestation of COVID-19.

The analysis also found that elevated liver enzymes are a common laboratory marker of COVID-19 patients. Huang et al. showed that AST elevation was observed in 8 (62%) of 13 patients in the intensive care unit compared with only 7 (25%) of 28 patients who did not require care in an ICU [140]. On the other hand, one study from China showed that COVID-19 patients with underlying chronic hepatitis B infection did not have higher disease severity compared to the overall population [143]. Unfortunately, most studies report liver enzymes as the mean/median value of the entire cohort without cutoff values for a given institution rather than as a proportion of patients with elevated values. One aspect that remains to be determined is the impact of COVID-19 in patients with preexisting chronic liver diseases, such as viral hepatitis, and fatty liver disease.

The pooled analysis showed that the overall fatality rate was 11.2%. While the finding is not statistically significant, any possible true difference in mortality may be worth further investigation among better defined COVID-19 patient subgroups with GI/LFT anomalies because one study showed that prevalence of severe disease was more common in patients who had gastrointestinal symptoms than those who did not [141]. Furthermore, a study by Wang et al found that abdominal pain was more frequent in patients who required ICU care than those who did not [142]. Although our finding was not statistically significant, the subgroup sub analysis

showed that patients who did not have gastrointestinal manifestations were more likely to be admitted to the ICU. This possible finding also requires additional data.

Limitations

Most of the studies we base our analyses on are observational, single arm cohorts. The lack of control groups and comparison arms can lead to bias due to confounding. Also, our subanalyses might have been affected by small sample sizes. Additionally, regarding fatality rate among COVID-19 patients, most of the studies did not differentiate between the GI symptoms and LFTs abnormalities when performing head to head comparison.

Conclusion

In this meta-analysis, we summarize the recent reports of digestive symptoms/LFT anomalies among patients infected with SARS-COV2. Gastrointestinal symptoms are commonly observed in patients with COVID-19, therefore, clinicians should be aware that diarrhea and nausea can be the only manifestations of COVID-19 patients. Our sub analysis showed that patients infected with SARS-COV2 and exhibiting digestive symptoms had higher mortality rate in the United States compared to China. We also could not find statistically significant association between ICU admission in patients with GI symptoms compared to those without digestive symptoms or hepatic manifestations due to small sample size; however, further investigation is warranted to better assess this possible association.

References

- 1- Lu, Roujian et al. "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding." *Lancet (London, England)* vol. 395,10224 (2020): 565-574. doi:10.1016/S0140-6736(20)30251-8
- 2- Wu, Zunyou, and Jennifer M. McGoogan. "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention." *Jama* 323.13 (2020): 1239-1242.
- 3- Kang, Shuntong et al. "Recent progress in understanding 2019 novel coronavirus (SARS-COV2) associated with human respiratory disease: detection, mechanisms and treatment." *International journal of antimicrobial agents* vol. 55,5 (2020): 105950. doi:10.1016/j.ijantimicag.2020.105950
- 4- Benvenuto, Domenico, et al. "The global spread of 2019-nCoV: a molecular evolutionary analysis." *Pathogens and Global Health* 114.2 (2020): 64-67.
- 5- "WHO Coronavirus Disease (COVID-19) Dashboard." *World Health Organization*, World Health Organization, 30 May 2020, covid19.who.int/?gclid=CjwKCAjwiMj2BRBFEiwAYfTbCs-zYYng4rwUJqKD946CSFHwJgC2YP9erGKVDphwwdudJsa3uWTxaBoCdLUQAvD_BwE.
- 6- Luo, Chao, et al. "Possible transmission of severe acute respiratory syndrome coronavirus 2 (SARS-COV2) in a public bath center in Huai'an, Jiangsu Province, China." *JAMA network open* 3.3 (2020): e204583-e204583.
- 7- Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." *New England journal of medicine* 382.18 (2020): 1708-1720.
- 8- Lidia Morawska, Donald K Milton, It is Time to Address Airborne Transmission of COVID-19, *Clinical Infectious Diseases*, 2020; ciaa939, <https://doi.org/10.1093/cid/ciaa939>
- 9- Bai, Yan, et al. "Presumed asymptomatic carrier transmission of COVID-19." *Jama* 323.14 (2020): 1406-1407.
- 10- Novel, Coronavirus Pneumonia Emergency Response Epidemiology. "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases

- (COVID-19) in China." *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi* 41.2 (2020): 145.
- 11-Lai, Chih-Cheng, et al. "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths." *Journal of Microbiology, Immunology and Infection* (2020).
 - 12-12- Zu, Zi Yue, et al. "Coronavirus disease 2019 (COVID-19): a perspective from China." *Radiology* (2020): 200490.
 - 13-Guan, Wei-jie, et al. "Clinical characteristics of 2019 novel coronavirus infection in China." *MedRxiv* (2020)
 - 14-Qi, Furong, et al. "Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses." *Biochemical and biophysical research communications* (2020).
 - 15-Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg.* 2003;73(9):712-716.
 - 16-Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. *Emerg Infect Dis* 2004;10:1550-7.
 - 17-Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-COV2 infection. *Gut.* 2020;69(6):997-1001. doi:10.1136/gutjnl-2020-321013
 - 18-Pan, Lei MD, PhD1,2; Mu, Mi MD3,4; Yang, Pengcheng MD5; Sun, Yu MD6; Wang, Runsheng MS7; Yan, Junhong MD8; Li, Pibao MD9; Hu, Baoguang MD, PhD10; Wang, Jing MS1; Hu, Chao MS7; Jin, Yuan MD6; Niu, Xun MD6; Ping, Rongyu MD2; Du, Yingzhen MD7; Li, Tianzhi MD2; Xu, Guogang MD, PhD2; Hu, Qinyong MD5; Tu, Lei MD, PhD11 Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China, *The American Journal of Gastroenterology*: 2020;115(5): 766-773. doi: 10.14309/ajg.0000000000000620
 - 19-Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X, Effect of gastrointestinal symptoms on patients infected with COVID-19, *Gastroenterology* (2020), doi: <https://doi.org/10.1053/j.gastro.2020.03.020>.

- 20- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;]. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
- 21- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
- 22- Lu, Roujian et al. "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding." Lancet (London, England) vol. 395,10224 (2020): 565-574. doi:10.1016/S0140-6736(20)30251-8
- 23- Wu, Zunyou, and Jennifer M. McGoogan. "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention." Jama 323.13 (2020): 1239-1242.
- 24- Kang, Shuntong et al. "Recent progress in understanding 2019 novel coronavirus (SARS-COV2) associated with human respiratory disease: detection, mechanisms and treatment." International journal of antimicrobial agents vol. 55,5 (2020): 105950. doi:10.1016/j.ijantimicag.2020.105950
- 25- Benvenuto, Domenico, et al. "The global spread of 2019-nCoV: a molecular evolutionary analysis." Pathogens and Global Health 114.2 (2020): 64-67.
- 26- "WHO Coronavirus Disease (COVID-19) Dashboard." World Health Organization, World Health Organization, 30 May 2020, covid19.who.int/?gclid=CjwKCAjwiMj2BRBFEiwAYfTbCs-zYYng4rwUJqKD946CSFHwJgC2YP9erGKVDphwwdudJsa3uWTxaBoCdLUQAvD_BwE.
- 27- Luo, Chao, et al. "Possible transmission of severe acute respiratory syndrome coronavirus 2 (SARS-COV2) in a public bath center in Huai'an, Jiangsu Province, China." JAMA network open 3.3 (2020): e204583-e204583.
- 28- Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." New England journal of medicine 382.18 (2020): 1708-1720.

- 29-Lidia Morawska, Donald K Milton, It is Time to Address Airborne Transmission of COVID-19, Clinical Infectious Diseases, 2020; ciaa939, <https://doi.org/10.1093/cid/ciaa939>
- 30-Bai, Yan, et al. "Presumed asymptomatic carrier transmission of COVID-19." *Jama* 323.14 (2020): 1406-1407.
- 31-Novel, Coronavirus Pneumonia Emergency Response Epidemiology. "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China." *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi* 41.2 (2020): 145.
- 32-Lai, Chih-Cheng, et al. "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths." *Journal of Microbiology, Immunology and Infection* (2020).
- 33-12- Zu, Zi Yue, et al. "Coronavirus disease 2019 (COVID-19): a perspective from China." *Radiology* (2020): 200490.
- 34-Guan, Wei-jie, et al. "Clinical characteristics of 2019 novel coronavirus infection in China." *MedRxiv* (2020)
- 35-Qi, Furong, et al. "Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses." *Biochemical and biophysical research communications* (2020).
- 36-Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non,Äêrandomized studies (minors): development and validation of a new instrument. *ANZ J Surg.* 2003;73(9):712,Äê716.
- 37-Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. *Emerg Infect Dis* 2004;10:1550-7.
- 38-Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-COV2 infection. *Gut.* 2020;69(6):997-1001. doi:10.1136/gutjnl-2020-321013
- 39-Pan, Lei MD, PhD1,2; Mu, Mi MD3,4; Yang, Pengcheng MD5; Sun, Yu MD6; Wang, Runsheng MS7; Yan, Junhong MD8; Li, Pibao MD9; Hu, Baoguang MD, PhD10; Wang, Jing MS1; Hu, Chao MS7; Jin, Yuan MD6; Niu, Xun MD6; Ping, Rongyu MD2; Du, Yingzhen MD7; Li, Tianzhi MD2; Xu, Guogang MD, PhD2; Hu, Qinyong MD5; Tu, Lei MD, PhD11 Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in

- Hubei, China, *The American Journal of Gastroenterology*: 2020;115(5): 766-773. doi: 10.14309/ajg.0000000000000620
- 40- Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X, Effect of gastrointestinal symptoms on patients infected with COVID-19, *Gastroenterology* (2020), doi: <https://doi.org/10.1053/j.gastro.2020.03.020>.
- 41- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in *Lancet*. 2020 Jan 30;:]. *Lancet*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
- 42- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
- 43- Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the
44- United States. *N Engl J Med*. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191
- 45- Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-COV2. *Gastroenterology*. 2020;158(6):1831-1833.e3. doi:10.1053/j.gastro.2020.02.055
- 46- Chen L, Luo JH, Bai Y, Wang M. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. *Am J Gastroenterol* 2020. In press.
- 47- Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, Zhang Q, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. *Gut* 2020. In press.
- 48- American college of gastroenterology. Joint GI Society Statement: Use of Personal Protective Equipment in GI Endoscopy. 2020; <https://gi.org/2020/04/01/joint-gi-society-message-on-ppe-during-COVID-19/>
- 49- Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci Adv* 2017;3:eaao4966.
- 50- Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45-e67.

- 51- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506
- 52- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020.
- 53- Cheung KS, Hung IF, Chan PP, et. al. Gastrointestinal Manifestations of SARS-COV2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis, *Gastroenterology*, 2020 March [Epub ahead of print]
- 54- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-69.
- 55- An PaC, Hongbin and Jiang, Xiaoda and Su, Juan and Xiao, Yong and Ding, Yijuan and Ren, Haixia and Ji, Mengyao and Chen, Yifei and Chen, Wei and Lv, ...and yu, Honggang, . Clinical Features of 2019 Novel Coronavirus Pneumonia Presented Gastrointestinal Symptoms But Without Fever Onset. *The Lancet*. 2020;<https://ssrn.com/abstract=3532530> or <http://dx.doi.org/10.2139/ssrn.3532530>
- 56- Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*. 2020;395(10223):514-523.
- 57- Chang D, Lin M, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA*. 2020;10.1001/jama.2020.1623.
- 58- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020;395(10223):507-513.
- 59- Chen Q, Quan B, Li X, et al. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. *Journal of Medical Virology*. 2020;DOI: 10.1002/jmv.25755.
- 60- Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection*. 2020;10.1007/s15010-020-01432-5.

- 61-Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal Manifestations of SARS-COV2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. *Gastroenterology*. 2020;10.1053/j.gastro.2020.03.065.
- 62-Cholankeril G, Podboy A, Aivaliotis VI, et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-COV2: Early Experience from California. *Gastroenterology*. 2020;10.1053/j.gastro.2020.04.008.
- 63-COVID-19 National Emergency Response Center E CMTK, Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. . *Osong Public Health Res Perspect* 2020. 2020;11:8-14.
- 64-Team C-NIRS. COVID-19, Australia: Epidemiology Report 7 (Reporting week ending 19:00 AEDT 14 March 2020). *Commun Dis Intell* (2018). 2020;44.
- 65-Fan H, Zhang L, Huang B, et al. Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19.2020;<https://doi.org/10.1101/2020.03.09.20033068>.
- 66-Fernandez-Ruiz M, Andres A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant*. 2020;10.1111/ajt.15929.
- 67-Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. *MedRxiv*.2020; <https://doi.org/10.1101/2020.04.01.20048561>.
- 68-Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine*. 2020.
- 69-Hajifathalian K, Krisko T, Mehta A, et al. Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications. *Gastroenterology*. 2020;10.1053/j.gastro.2020.05.010.
- 70-Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol*. 2020;10.14309/ajg.0000000000000664.
- 71-Hsieh W-H, Cheng M-Y, Ho M-W, et al. Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. *Journal of Microbiology, Immunology and Infection*.2020; <https://doi.org/10.1016/j.jmii.2020.03.008>.

- 72- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
- 73- Huang R, Xia J, Chen Y, Shan C, Wu C. A family cluster of SARS-COV2 infection involving 11 patients in Nanjing, China. *Lancet Infect Dis*. 2020;20(5):534-535.
- 74- Huang WH, Teng LC, Yeh TK, et al. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. *J Microbiol Immunol Infect*. 2020 10.1016/j.jmii.2020.02.009.
- 75- Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-COV2 infection in Wuhan, China: A retrospective single center analysis. *Travel Med Infect Dis*. 2020;10.1016/j.tmaid.2020.101606:101606.
- 76- Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. 2020;69(6):1002-1009.
- 77- Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci*. 2020;35(13):e142.
- 78- Klopfenstein T, Kadiane-Oussou NJ, Royer PY, Toko L, Gendrin V, Zayet S. Diarrhea: An underestimated symptom in Coronavirus disease 2019. *Clin Res Hepatol Gastroenterol*. 2020;10.1016/j.clinre.2020.04.002.
- 79- Kluytmans M, Buiting A, Pas S, et al. SARS-COV2 infection in 86 healthcare workers in two Dutch hospitals in March 2020 <https://doi.org/10.1101/2020.03.23.20041913>. medRxiv. 2020.
- 80- Kuang Y, Zhang H, Zhou R, et al. Epidemiological and Clinical Characteristics of 944 Cases of 2019 Novel Coronavirus Infection of Non-COVID-19 Exporting City, Zhejiang, China. Zhejiang, China (February 20, 2020). 2020;doi.org/10.2139/ssrn.3543604.
- 81- Kui L, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chinese medical journal*. 2020; doi: 10.1097/CM9.0000000000000744.

- 82-Kujawski SA, Wong KK, Collins JP, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States <https://doi.org/10.1101/2020.03.09.20032896>. MedRxiv. 2020.
- 83-Lechien JR, Chiesa-Estomba CM, De Sisti DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mildto- moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;10.1007/s00405-020-05965-1.
- 84-Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol. 2020;55(6):327-331.
- 85-Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-COV2 infection. Gut. 2020;69(6):997-1001.
- 86-Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-374.
- 87-Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clinical Gastroenterology and Hepatology. 2020;doi: 10.1016/j.cgh.2020.03.043.
- 88-Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal Symptoms and COVID-19: Case control Study from the United States. Gastroenterology. 2020;10.1053/j.gastro.2020.04.017.
- 89-Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020:200370.
- 90-Pan L, Mu M, Ren H. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross sectional, multicenter study. 2020.
- 91-Pung R, Chiew CJ, Young BE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. 2020;395(10229):1039-1046.
- 92-Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARSCoV- 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology. 2020;10.1053/j.gastro.2020.04.045.

- 93- Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin Med J (Engl)*. 2020;133(9):1015-1024.
- 94- Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases*. 2020;20(4):425-434.
- 95- Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020; doi:10.1001/jamacardio.2020.0950.
- 96- Shu L, Wang X, Li M, et al. Clinical Characteristics of 545 Cases Confirmed COVID-19 in Wuhan Stadium Cabin Hospital. Available at SSRN 3552844. 2020; <https://ssrn.com/abstract=3552844>.
- 97- Siegel A, Chang PJ, Jarou ZJ, et al. Lung Base Findings of Coronavirus Disease (COVID-19) on Abdominal CT in Patients With Predominant Gastrointestinal Symptoms. *AJR Am J Roentgenol*. 2020;10.2214/AJR.20.23232:1-3.
- 98- Song F, Shi N, Shan F, et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology*. 2020;doi: 10.1148/radiol.2020200274:200274.
- 99- Spiteri G, Fielding J, Diercke M, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. *Euro Surveill*. 2020;25(9).
- 100- Tabata S, Imai K, Kawano S, et al. The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan <https://doi.org/10.1101/2020.03.18.20038125>. medRxiv. 2020.
- 101- Wan Y, Li J, Shen L, et al. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. *The lancet Gastroenterology & hepatology*. 2020;10.1016/S2468-1253(20)30118-7.
- 102- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020; 10.1001/jama.2020.1585.
- 103- Wang L, Gao YH, Lou LL, Zhang GJ. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. *Eur Respir J*. 2020;55(4).

- 104- Wang L, Duan Y, Zhang W, et al. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China. *Clin Epidemiol*. 2020;12:387-391.
- 105- Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week followup. *J Infect*. 2020;10.1016/j.jinf.2020.03.019.
- 106- Wang X, Fang J, Zhu Y, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. *Clin Microbiol Infect*. 2020;10.1016/j.cmi.2020.03.032.
- 107- Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. *Bioscience trends*. 2020;DOI: 10.5582/bst.2020.01030.
- 108- Wei X-S, Wang X, Niu Y-R, et al. Clinical Characteristics of SARS-COV2 Infected Pneumonia with Diarrhea. Available at SSRN 3546120. 2020; <http://dx.doi.org/10.2139/ssrn.3546120>.
- 109- Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;10.1038/s41586-020-2196-x.
- 110- Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clinical Infectious Diseases*. 2020.
- 111- Wu J, Wu X, Zeng W, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. *Invest Radiol*. 2020;55(5):257-261.
- 112- Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-COV2 viral RNA in faecal samples. *The lancet Gastroenterology & hepatology*. 2020;10.1016/s2468-1253(20)30083-2.
- 113- Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. *J Clin Virol*. 2020;127:104360.
- 114- Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-COV2. *Gastroenterology*. 2020;10.1053/j.gastro.2020.02.055.

- 115- Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int.* 2020;10.1111/liv.14449.
- 116- Xiong Y, Sun D, Liu Y, et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Followup Changes. *Invest Radiol.* 2020;55(6):332-339.
- 117- Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-COV2. *Eur J Nucl Med Mol Imaging.* 2020;47(5):1275-1280.
- 118- Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. *Bmj.* 2020;368.
- 119- Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. *J Med Virol.* 2020;10.1002/jmv.25972.
- 120- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-COV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020;8(5):475-481.
- 121- Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-COV2 in Singapore. *Jama.* 2020.
- 122- Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. *J Infect Dis.* 2020;221(11):1757-1761.
- 123- Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *J Clin Virol.* 2020;127:104364.
- 124- Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS CoV-2 in Wuhan, China. *Allergy.* 2020;10.1111/all.14238.
- 125- Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. *J Med Virol.* 2020;10.1002/jmv.25742.
- 126- Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. *Clinical Infectious Diseases.* 2020; <https://doi.org/10.1093/cid/ciaa247>.

- 127- Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease(COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol*. 2020;214(5):1072-1077.
- 128- Zhao XY, Xu XX, Yin HS, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis*. 2020;20(1):311.
- 129- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020.
- 130- Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. *AJR Am J Roentgenol*. 2020; 10.2214/AJR.20.22975:1-8.
- 131- Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms on patients infected with COVID-19. *Gastroenterology*. 2020;<https://doi.org/10.1053/j.gastro.2020.03.020>.
- 132- Zou L, Ruan F, Huang M, et al. SARS-COV2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-1179.
- 133- Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191
- 134- Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-COV2. *Gastroenterology*. 2020;158(6):1831-1833.e3. doi:10.1053/j.gastro.2020.02.055
- 135- Chen L, Luo JH, Bai Y, Wang M. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. *Am J Gastroenterol* 2020. In press.
- 136- Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, Zhang Q, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coro2navirus. *Gut* 2020. In press.
- 137- American college of gastroenterology. Joint GI Society Statement: Use of Personal Protective Equipment in GI Endoscopy. 2020; <https://gi.org/2020/04/01/joint-gi-society-message-on-ppe-during-COVID-19/>
- 138- Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci Adv* 2017;3:eaa04966.

- 139- Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45-e67.
- 140- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506
- 141- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020.
- 142- Cheung KS, Hung IF, Chan PP, et. al. Gastrointestinal Manifestations of SARS-COV2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis, *Gastroenterology*, 2020 March [Epub ahead of print]
- 143- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-69.

Figure.1

Figure.2

Figure.3

Figure.4

Figure.5

Study	Total no. of patients	Mortality in patients with GI symptoms	country
Huang C et. al.	41	0	China
Fan H et. al.	101	9	China
Han C et. al.	206	0	China
Huang WH et. al.	2	0	China
Jin X et. al.	651	0	China
Kuang Y et. al.	944	0	China
Lin L et. al.	95	0	China
Luo S et. al.	1141	7	China
Pan F et. al.	21	0	China
Shu L et. al.	545	0	China
Song F et. al.	51	0	China
Wan Y et. al.	230	4	China
Wei X-S et. al.	84	0	China
Wu Y et. al.	74	0	China
Xia X et. al.	10	0	China
Zhao D et. al.	19	0	China
Zhou F et. al.	191	2	China
Zhou Z et. al.	254	5	China
Total China	4660	27	0.58%
Cholankeril G et. al.	116	0	US
Kujawski S et. al.	12	0	US
Redd W et. al.	318	16	US
Siegel et. al.	3	0	US
Total USA	449	16	3.5%
Hsih W-H et. al.	2	0	Taiwan
Tabata S et. al.	104	0	Japan
Kim ES et. al.	28	0	Korea

Table. 1 Mortality by geographic location

PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	1
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	3,4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	3,4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	3,4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	5

PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6,7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	5
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8,9,10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8,9,20
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	5
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8,9,20
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10,11,12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10,11
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	NA

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

medRxiv preprint doi: <https://doi.org/10.1101/2020.10.29.20207167>; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplemental Material

Table. S1. Studies included in the meta-analysis

Study	Journal	Study type	Date	Country
Siegel et al	American Roentgen Ray Society	Case series	3-Apr-20	USA
Pazgan-simon et al	Polish Archives of Internal Medicine	Case report	3-Apr-20	Poland
Yang, X et al	Clinics and Research in Hepatology and Gastroenterology	Case report	15-Apr-20	China
Zhang, J et al	Allergy (John Wiley and Sons Ltd.)	Retrospective cohort study	18-Feb-20	China
Azwar et al	Indones J Intern Med	Case report	Jan-20	Indonesia
Jin, X et al	BMJ	Retrospective cohort study	17-Mar-20	China
Nobel et al	Gastroenterology	Case-Control Study	8-Apr-20	USA
Lin et al	BMJ	Retrospective cohort study	24-Mar-20	China
Zhou et al	Gastroenterology	Retrospective cohort study	12-Mar-20	China
Pan et al	The American Journal of GASTROENTEROLOGY	Cross-sectional study	14-Apr-20	China
Poggiali et al	European Journal of Case Reports in Internal Medicine	Case series	26-Mar-20	Italy
Cholankeril et al	Gastroenterology	Retrospective cohort study	4-Apr-20	USA
Fu et al	Digestive Diseases and Sciences (Springer)	Case report	28-Apr-20	China
Li et al	World Journal of Clinical Cases	Case report	6-Apr-20	China
Saeed et al	British Journal of Surgery	Retrospective cohort study	28-Apr-20	Norway
Arashiro et al.	Journal of travel medicine	case-report	16-Apr-20	Japan
Yang F et al	Journal Of Medical Virology	Retrospective Cohort Study	15-Apr-20	China
Guillen, E et al	American Journal of Transplantation	Case Report	20-Mar-20	Spain
Chen, Y et al	Journal Of Medical Virology	Retrospective Cohort Study	3-Apr-20	China
Chen Q et al	Journal of Medical Virology	SHORT COMMUNICATION	12-Mar-20	China
Huang et al	The Lancet	Prospective Cohort study	15-Feb-20	China

Chen, N et al	The Lancet	Retrospective Cohort Study	15-Feb-20	China
Wang et al	JAMA	Case series	17-Mar-20	China
Xu, X et al	BMJ	retrospective case series	13-Feb-20	China
Fan et al	MedRxiv	Retrospective Cohort Study	28-Feb-20	China
Zhang, B et al	MedRxiv	Retrospective Cohort Study	27-Feb-20	China
Huang Y et al	MedRxiv	Retrospective Cohort Study	5-Mar-20	China
Wan, S et al	Journal of Medical Virology	Retrospective Cohort Study	6-Mar-20	China
Zhang, Y et al	Liver International	Retrospective Cohort Study	30-Mar-20	China
Xu, Z et al	The Lancet	Case Report	17-Feb-20	China
Arentz et al	JAMA	Retrospective Cohort Study	17-Mar-20	USA
Hajifathalian et al	Gastroenterology	Retrospective Cohort Study	1-May-20	USA
Kujawski et al	MedRxiv	Retrospective Cohort Study	12-Mar-20	USA
Young et al	JAMA	Case series	3-Mar-20	Singapore
Sun et al	Clinical Infectious Diseases	retrospective case-control	25-Mar-20	Singapore
Pung et al	The Lancet	Retrospective Cohort Study	16-Mar-20	Singapore
Tabata et al	MedRxiv	Retrospective Cohort Study	7-Apr-20	Japan
Kluytmans et al	MedRxiv	cross-sectional study	31-Mar-20	Netherlands
Qian et al	Quarterly Journal of Medicine	Retrospective case series	17-Mar-20	China
Luo et al	Clinical Gastroenterology and Hepatology	Retrospective cohort study	20-Mar-20	China
Zhou F et al	Lancet	Retrospective Cohort Study	11-mar-20	China
Chen T et al	BMJ	Retrospective Case Series	26-Mar-20	China
Xu H et al	MedRxiv	Retrospective Cohort Study	30-Mar-20	China
Shi S et al	JAMACardio	Retrospective Cohort Study	25-Mar-20	China
Han R et al	Lancet	Retrospective Cohort Study	12-Jun-20	China
Xu S et al	MedRxiv	Retrospective analysis	pre-print	China
Ma L et al	MedRxiv	Retrospective Study	30-MAr-20	China

Liu L et al	Microbes and infection	Retrospective Study	18-May-20	China
Mao L et al	JAMANEurology	Case Series	10-Apr-20	China
Ai JW et al	Frontiers in Medicine	Cross sectional study	9-Jun-20	China
Liu Y et al	MedRxiv	Retrospective Study	preprint	China
Shu L et al	Lancet	Retrospective Cohort Study	preprint	China
Wei L et al				China
Zhao Z et al	MedRxiv	Retrospective Study	6-Mar-20	China
Zhao W et al	MedRxiv	Retrospective Cohort Study	30-Mar-20	China
Yang P et al	MedRxiv	Retrospective Study	3-Mar-20	China
Li K et al	Investigative Radiology	Retrospective Study	1-June-20	China
Qi D et al	MedRxiv	Retrospective Descriptive study	3-Mar-20	China
Wen Y et al	MedRxiv	Retrospective Study	23-Mar-20	China
Xu Y et al	MedRxiv	Retrospective Observational Study	6-Mar-20	China
Yan S et al	MedRxiv	Retrospective Study	23-Mar-20	China
Wang L et al	European Respiratory Journal	Retrospective Study	23-Apr-20	China
Chen X et al	MedRxiv	Observational study	6-Mar-20	China
Liu S et al	BMC Infectious Diseases	Cohort Study	6-Jun-20	China
Yao et al	Chinese Journal of Hepatology	Retrospective Study	20-Mar-20	China
Tian S et al	MedRxiv	Retrospective study	23-Mar-20	China
Lu H et al	MedRxiv	Descriptive Study	23-Feb-20	China
Fu H et al	MedRxiv	Observational Study	23-Mar-20	China
Fu H et al	MedRxiv	Observational Study	1-Mar-2020	China
Chen D et al	MedRxiv	Retrospective Study	29-Feb-20	China
Kuang et al				China
Rubin et al	Journal of Clinical And Translational Science	Cohort	7-Jun-20	USA
Covid-19 National Emergency Response Center South Korea	Osong Public Health and Research Perspectives	Case Series	11-Feb-20	South Korea

Pung et al	Lancet	Retrospective	17-Mar-20	Singapore
Wolfel et al	Nature	Case series	1-Apr-20	Germany
Dreher et al	Dtsch Arztebl International	Retrospective	Apr-20	Germany
Gritti et al	MedRxiv	Observational Cohort Study	Jun-20	Italy
Spiteri et al	Euro Surveillance	Surveillance	5-Mar-20	Germany, Finland, Italy, Russia, Spain, France, Sweden, and Belgium
Covid-19 National Incident Room Surveillance Team Australia	Communicable Diseases Intelligence (2018)	Epidemiology Report	Mar-20	Australia
An P et. al.		Case series	Jan-20	China
Chan et. al.		Case series	Jan-20	China
Chang et al		Case series	Jan-20	China
Chen et al		Case series	Jan-20	China
Cheung et al		Case series	Feb-20	China
Fan H et al		Case series	16-Feb-20	China
Fernandez-Ruiz et al		Case series	Mar-20	Spain
Guan et al		Retrospective cohort	29-Jan-20	China
Han et al		Retrospective cohort	Feb-20	China
Hsih et al		Case series	19-Feb-20	Taiwan
Huang et al		Case series	1-Feb-20	China
Huang et al		Case series	-	China
Kim ES et al		Case series	17-Feb-20	Korea
Klopfenstein et al		Case series	17-Mar-20	France
Liu K et al		Case series	24-Jan-20	China
Lechien et al		Case series	-	Europe

Liu Y et al		Case series	Jan-20	China
Pan F et al		Retrospective cohort	2-feb-20	China
Redd et al		Retrospective cohort	2-Apr-20	US
Ren et al		Case series	29-Dec-19	China
Shi H et al		Retrospective cohort	23-Jan-20	China
Song et al		Case series	27-Jan-20	China
Wan Y et al		Case series	6-Mar-20	China
Wang L (b) et. al.		Case series	12-Feb-20	China
Wang L (c) et. al.		Case series	6-Feb-20	China
Wang X et. al.		Case series	12-Feb-20	China
Wang Z et. al.		Case series	24-Jan-20	China
Wei X-S et. al.		Case series	7-Feb-20	China
Wu J (a) et. al.		Retrospective cohort	14-Feb-20	China
Wu J (b) et al		Case series	Feb-20	China
Wu Y et. al.		Case series	15-Mar-20	China
Xia X et. al.		Case series	-	China
Xiao F et. al.		Case series	14-Feb-20	China
Xie H et. al.		Case series	23-Feb-20	China
Xiong Y et. al.		Case series	5-Feb-20	China
Xu X et al		Case series	4-Feb-20	China
Yu P et. al.		Case series	23-Jan-20	China
Zhang J (b) et. al		Case series	10-Feb-20	China
Zhao X-Y et. al.		Case series	10-Feb-20	China
Zhou S et. al.		Case series	30-Jan-20	China
Zou L et. al.		Case series	26-Jan-20	China

Table. S2 The Methodical Index for Non-randomized Studies (MINORS)

Study	1	2	3	4	5	6	7	8	Total
Siegel et al	1	1	0	0	0	0	0	0	2
Pazgan-simon et al	1	0	0	1	0	0	0	0	2
Yang, X et al	1	0	0	1	0	0	0	0	2
Zhang, J et al	2	2	2	1	0	0	0	1	8
Azwar et al	1	1	0	1	0	1	0	0	4
Jin, X et al	2	2	2	2	0	1	1	1	11
Nobel et al	2	2	2	1	0	0	0	1	8
Lin et al	1	1	0	2	0	1	0	1	6
Zhou et al	2	1	0	1	0	0	0	1	5
Pan et al	2	1	1	0	0	0	0	1	5
Poggiali et al	2	0	0	1	0	1	0	2	6
Cholankeril et al	2	1	2	0	0	0	0	0	5
Fu et al	2	0	1	1	0	0	0	0	4
Li et al	2	0	2	0	0	0	0	0	4
Saeed et al	2	1	0	1	0	0	0	1	5
Arashiro et al.	2	0	0	2	0	0	0	1	5
Yang F et al	1	0	2	0	0	0	0	1	4
Guillen, E et al	2	1	1	1	0	1	0	2	8
Chen, Y et al	1	1	0	2	0	1	0	1	6
Chen Q et al	2	1	0	1	0	0	0	1	5
Huang et al	2	1	1	0	0	0	0	1	5
Chen, N et al	2	0	1	1	0	0	0	2	6
Wang et al	2	0	2	0	0	0	0	2	6
Xu, X et al	2	1	0	1	0	0	0	2	6
Fan et al	2	0	1	1	0	0	0	2	6
Zhang, B et al	2	1	2	0	0	0	0	2	7
Huang Y et al	2	0	1	1	0	0	0	2	6
Wan, S et al	2	0	2	0	0	0	0	2	6
Zhang, Y et al	2	1	0	1	0	0	0	2	6
Xu, Z et al	2	0	0	0	0	0	0	2	4

Arentz et al	1	0	2	0	0	0	0	1	4
Hajifathalian et al	2	1	1	1	0	0	0	2	7
Kujawski et al	1	1	0	1	0	0	0	1	4
Young et al	2	1	0	1	0	0	0	2	6
Sun et al	2	0	0	0	0	0	0	2	4
Pung et al	1	0	2	0	0	0	0	1	4
Tabata et al	2	1	0	1	0	0	0	1	5
Kluytmans et al	2	1	1	0	0	0	0	1	5
Qian et al	2	0	0	1	0	1	0	2	6
Luo et al	0	1	1	1	2	3	0	1	9
Zhou F et al	2	0	1	4	0	4	0	2	13
Chen T	1	1	1	2	1	0	0	2	8
Xu H et al	2	1	0	3	0	0	0	1	7
Shi S et al	2	1	1	0	0	0	0	2	6
Han R et al	1	0	0	0	0	1	0	2	4
Xu S et al	0	1	1	1	2	3	0	1	9
Ma L et al	2	0	1	3	0	3	0	1	9
Liu L et al	2	0	2	0	0	0	0	2	6
Mao L et al	2	1	0	1	0	0	0	2	6
Ai JW et al	c	0	0	0	0	0	0	2	4
Shu L et al	1	0	2	0	0	0	0	1	4
Wei L et al	2	1	1	1	0	0	0	2	7
Zhao Z et al	1	1	0	1	0	0	0	1	4
Zhao W et al	2	0	2	0	0	0	0	2	6
Yang P et al	2	1	0	1	0	0	0	2	6
Li K et al	2	0	0	0	0	0	0	2	4
Qi D et al	2	1	0	1	0	0	0	1	5
Wen Y et al	2	1	1	0	0	0	0	1	5
Xu Y et al	1	0	0	0	0	1	0	2	4
Yan S et al	0	1	1	1	2	3	0	1	9
Wang L et al	2	0	1	3	0	4	0	2	11
Chen X et al	2	1	0	3	0	0	0	1	7
Liu S et al	2	1	1	0	0	0	0	2	6
Fan L et al	1	0	1	0	0	1	0	2	5
Yao et al	0	1	1	1	2	3	0	1	9
Tian S et al	2	0	1	3	0	4	0	1	10

Lu H et al	2	1	0	1	0	0	0	2	6
Fu H et al	2	1	1	0	0	0	0	1	5
Fu H et al	2	1	0	3	0	0	0	1	7
Chen D et al	2	1	1	0	0	0	0	2	6
Kuang et al	1	0	0	0	0	1	0	2	4
Rubin et al	0	1	1	1	2	3	0	1	9
COVID-19 National Emergency Response Center	2	0	1	3	0	4	0	2	12
Pung et al	2	2	0	1	0	0	0	1	6
Wolfel	2	1	0	1	0	0	0	1	5
Dreher et al	2	1	1	0	0	0	0	1	5
Gritti et al	2	0	0	1	0	1	0	2	6
Spiteri et al	0	1	1	1	2	3	0	1	9
Covid-19 National Incident Room Surveillance Team Australia	2	0	1	4	0	4	0	2	13
An P et. al.	1	1	1	2	1	0	0	2	8
Chan F-W et.al.	2	1	0	3	0	0	0	1	7
Chang D et. al.	2	1	1	0	0	0	0	2	6
Chen Q (b) et. al.	1	0	0	0	0	1	0	2	4
Cheung K et. al.	0	1	1	1	2	3	0	1	9
Fan H et. al.	2	0	1	3	0	3	0	1	9
FernandezRuiz et. al.	2	0	2	0	0	0	0	2	6
Guan W-j et. al.	2	1	0	1	0	0	0	2	6
Han C et. al.	c	0	0	0	0	0	0	2	4
Hsieh W-H et. al.	1	0	2	0	0	0	0	1	4
Huang R et. al.	2	1	1	1	0	0	0	2	7
Huang WH et. al.	1	1	0	1	0	0	0	1	4
Kim ES et. al.	2	0	2	0	0	0	0	2	6
Klopfenstein T et. al.	2	1	0	1	0	0	0	2	6
Liu K et. al.	2	0	0	0	0	0	0	2	4
Lechien J et. al.	2	1	0	1	0	0	0	1	5
Liu Y et. al.	2	1	1	0	0	0	0	1	5
Pan F et. al.	1	0	0	0	0	1	0	2	4
Redd W et. al.	0	1	1	1	2	3	0	1	9
Ren L et. al.	2	0	1	3	0	4	0	2	11

Shi H et. al.	2	1	0	3	0	0	0	1	7
Song F et. al.	2	1	1	0	0	0	0	2	6
Wan Y et. al.	1	0	1	0	0	1	0	2	5
Wang L (b) et.	0	1	1	1	2	3	0	1	9
Wang L (c) et. al.	2	0	1	3	0	4	0	1	10
Wang X et. al.	2	1	0	1	0	0	0	2	6
Wang Z et. al.	2	1	1	0	0	0	0	1	5
Wei X-S et. al.	2	1	0	3	0	0	0	1	7
Wu J (a) et. al.	2	1	1	0	0	0	0	2	6
Wu J (b) et al	1	0	0	0	0	1	0	2	4
Wu Y et. al.	0	1	1	1	2	3	0	1	9
Xia X et. al.	2	0	1	3	0	4	0	2	12
Xiao F et. al.	2	2	0	1	0	0	0	1	6
Xie H et. al.	1	0	0	0	0	1	0	2	4
Xiong Y et. al.	2	1	0	3	0	0	0	1	7
Xu X et al	2	1	1	0	0	0	0	2	6
Yu P et. al.	1	0	0	0	0	1	0	2	4
Zhang J (b) et. al.	0	1	1	1	2	3	0	1	9
Zhao X-Y et. al.	2	0	1	3	0	4	0	1	10
Zhou S et. al.	2	1	0	1	0	0	0	1	5
Zou L et. al.	2	1	1	0	0	0	0	1	5

Table. S3 Gastrointestinal symptoms

Study	Total number s (n)	Abdominal pain (n)	Diarrhea (n)	Nausea (n)	Vomiting (n)	Anorexia or loss of appetite (n)	Loss of taste (n)	Elevated liver enzymes (n)
Siegel et al	3	3	3	2	2	0	0	0
Pazgan-simon et al	1	1	0	1	0	1	0	0
Yang, X et al	1	1	0	0	0	0	0	0
Zhang, J et al	140	8	18	24	7	17	0	8
Azwar et al	1	1	0	0	1	0	0	0
Jin, X et al	651	0	56	13	14	0	0	64
Nobel et al	278	0	56	63	63	0	0	0
Lin et al	95	2	23	17	4	17	0	31
Zhou et al	254	3	46	21	15	0	0	0
Pan et al	204	2	35	0	4	81	0	0

Poggiali et al	10	1	6		3	0	0	0
Cholankeril et al	116	10	12	1	1	22	0	26
Fu et al	1	0	0	0	1	0	0	0
Li et al	1	0	1	0	0	1	0	0
Saeed et al	9	9	1	8	5	0	0	0
Arashiro et al.	1	0	1	1	0	1	0	0
Yang F et al	92	0	0	0	0	0	0	15
Guillen, E et al	1	0	0	0	1	0	0	0
Chen, Y et al	42	5	7	4	3	0	0	0
Chen Q et al	9	0	2	0	0	0	0	0
Huang C et al	41	0	1	0	0	0	0	0
Chen, N et al	99	0	2	1	1	0	0	63
Wang et al	138	3	14	14	5	55	0	
Xu, X et al	62	0	3	0	0	0	0	0
Fan et al	148	0	6	6	0	0	0	75
Zhang, B et al	82	0	10	0	2	0	0	0
Huang Y et al	36	0	3	0	0	0	0	22
Wan, S et al	135	0	18	4	0	6	0	0
Zhang, Y et al	115	0	0	0	0	0	0	28
Xu, Z et al	1	0	0	0	0	0	0	1
Arentz et al	21	0	0	0	0	0	0	8
Hajifathalian et al	1059	72	234	168	91	240	57	656
Kujawski et al	12	1	1	0	0	0	0	0
Young et al	18	0	3	0	0	0	0	0
Sun et al	54	0	0	0	0	0	0	0
Pung et al	36	0	4	1	0	0	0	0
Tabata et al	104	0	18	0	0	0	0	9
Kluytmans et al	86	5	16	0	0	15	6	0
Qian et al	91	0	21	11	6	23	0	0
Luo et al	183	45	68	134	119	-	-	183
Zhou F et al	191	-	9	7	7	-	-	59
Chen T	274	19	77	24	16	-	-	84
Xu H et al	1324	-	28	-	-	55	-	-
Shi S et al	416	-	29	-	-	-	-	416
Han R et al	108	-	15	-	-	-	-	-
Xu S et al	355	-	130	-	-	-	-	102
Ma L et al	81	-	6	-	-	-	-	31
Liu L et al	153	1	14	2	3	-	-	-
Mao L et al	214	10	41	-	-	-	-	26
Ai JW et al	102	4	15	9	2	-	-	26

Shu L et al	545	-	49	0	0	-	-	41
Wei L et al	100	-	2	-	2	-	-	17
Zhao Z et al	75	1	7	-	-	-	-	15
Zhao W et al	77	-	1	6		-	-	26
Yang P et al	55	-	2	-	-	-	-	-
Li K et al	83	-	7	-	-	-	-	-
Qi D et al	267	-	10	6		46	-	20
Wen Y et al	417	-	29	-	-	-	-	-
Xu Y et al	45	-	0	-	-	-	-	17
Yan S et al	168	7	12	9	7	-	-	18
Wang L et al	18	-	3	-	-	-	-	4
Chen X et al	291	1	25	17		-	-	44
Liu S et al	620	-	53	-	-	-	-	420
Fan L et al	55	-	6	-	4	-	-	
Yao et al	40	-	3	3	-	-	-	21
Tian S et al	37	-	8	-	-	-	-	4
Lu H et al	265	-	17	6	-	-	-	
Fu H et al	52	-	7	1	-	-	-	
Fu H et al	36	-	3	-	-	-	-	4
Chen D et al	175	-	35	-	-	-	-	-
Kuang et al	944	-	21	-	-	-	-	-
Rubin et al	54	-	-	-	-	-	-	-
COVID-19 National Emergency Response Center	28	1	2	-	-	-	-	-
Pung et al	17	-	4	1		-	-	-
Wolfel	9	-	2	-	-	-	-	-
Dreher et al	50	-	8	1	2	-	-	-
Gritti et al	21	-	5	-	-	-	-	-
Spiteri et al	38	-	1	1	-	-	-	-
Covid-19 National Incident Room Surveillance Team Australia	295	6	48	34	-	-	-	-
An P et. al.	9	-	1	1	1	6	-	-
Chan F-W et.al.	6	-	2	-	-	-	-	-
Chang D et. al.	13	-	1	-	-	-	-	-
Chen Q (b) et. al.	145	-	39	24	6	-	-	-
Cheung K et.	59	7	13	-	1	-	-	-

al.								
Fan H et. al.	101	-	2	7 nausea or vomiting		-	-	-
FernandezRui z et. al.	17	1	3	-	-	-	-	-
Guan W-j et. al.	1099	-	42	55	55	-	-	-
Han C et. al.	206	9	67	-	24	32	-	-
Hsieh W-H et. al.	2	1	1	-	-	-	-	-
Huang R et. al.	11	-	1	-	-	-	-	-
Huang WH et. al.	2	-	-	-	-	2	-	-
Kim ES et. al.	28	1	3	-	-	-	-	-
Klopfenstein T et. al.	114	19	55	25	9	-	-	-
Liu K et. al.	137	-	11	-	-	-	-	-
Lechien J et. al.	417	125	208	91	91	-	-	-
Liu Y et. al.	12	-	2	2 nausea and vomiting		-	-	-
Pan F et. al.	21	-	-	-	-	9	-	-
Redd W et. al.	318	46	107	84	49	110	-	-
Ren L et. al.	5	-	0	-	-	-	-	-
Shi H et. al.	81	-	3	-	4	-	-	-
Song F et. al.	51	-	5	3 nausea and vomiting		9	-	-
Wan Y et. al.	230	-	49	-	-	-	-	-
Wang L (b) et.	26	-	0	-	-	-	-	-
Wang L (c) et. al.	339	-	43	13	-	94	-	-
Wang X et. al.	1021	37	152	-	36	-	-	-
Wang Z et. al.	4	-	0	-	-	-	-	-
Wei X-S et. al.	84	2	26	16	6	-	-	-
Wu J (a) et. al.	80	-	1	1	1	-	-	-
Wu J (b) et al	80	-	7	-	-	-	-	-
Wu Y et. al.	74	-	26	-	-	-	-	-
Xia X et. al.	10	-	1	1	-	-	-	-
Xiao F et. al.	73	-	26	-	-	-	-	-
Xie H et. al.	79	-	7	-	-	-	-	-
Xiong Y et. al.	42	-	10	-	-	-	-	-
Xu X et al	90	-	5	5	2	-	-	-
Yu P et. al.	4	-	-	-	-	4	-	-
Zhang J (b) et. al.	14	-	0	-	0	-	-	-
Zhao X-Y et. al.	91	2	13	10	-	10	-	-
Zhou S et. al.	62	9 abdominal pain or diarrhea		-	-	-	-	-

Zou L et. al.	18	-	1	1	-	1	-	-
----------------------	-----------	---	---	---	---	---	---	---

Table. S4 Sensitivity Analysis

References	No. of patients	Abdominal pain (n)	Diarrhea (n)	Nausea (n)	Vomiting (n)	Anorexia or loss of appetite (n)	Loss of taste (n)	Elevated liver enzymes (n)
Zhang, J et al	140	8	18	24	7	17		8
Jin, X et al	651	0	56	13	14	0	0	64
Lin et al	95	2	23	17	4	17	0	31
Zhou et al	254	3	46	21	15	0	0	0
Pan et al	204	2	35	0	4	81	0	0
Cholankeril et al	116	10	12	1	1	22	0	26
Saeed et al	9	9	1	8	5	0	0	0
Yang F et al	92	0	0	0	0	0	0	15
Chen, Y et al	42	5	7	4	3	0	0	0
Huang, C et al	41	0	1	0	0	0	0	0
Chen, N et al	99	0	2	1	1	0	0	63
Xu, X et al	62	0	3	0	0	0	0	0
Fan et al	148	0	6	6	0	0	0	75
Zhang, B et al	82	0	10	0	2	0	0	0
Huang Y et al	36	0	3	0	0	0	0	22
Wan, S et al	135	0	18	4	0	6	0	0
Zhang, Y et al	115	0	0	0	0	0	0	28
Arentz et al	21	0	0	0	0	0	0	8

Hajifathalian et al	1059	72	234	168	91	240	57	656
Kujawski et al	12	1	1	0	0	0	0	0
Sun et al	54	0	0	0	0	0	0	0
Pung et al	36	0	4	1	0	0	0	0
Tabata et al	104	0	18	0	0	0	0	9
Kluytmans et al	86	5	16	0	0	15	6	0
Qian et al	91	0	21	11	6	23	0	0
Total	3784	117	535	279	153	421	63	1005

Table. S5 Fatality numbers as reported by each study

Study	Total no. of patients	Fatality (n)	Country
Siegel et al	3	0	USA
Pazgan-simon et al	1	0	Poland
Azwar et al	1	0	China
Jin, X et al	651	1	China
Nobel et al	278	9	Indonesia
Lin et al	95	0	China
Zhou et al	254	16	USA
Pan et al	204	36	China
Cholankeril et al	116	1	China
Fu et al	1	0	China
Li et al	1	1	Italy
Saeed et al	9	1	USA
Arashiro et al.	1	1	China
Yang F et al	92	92	China
Chen Q et al	9	0	Norway
Huang, C et al	41	6	Japan
Chen, N et al	99	11	China

Wang et al	138	6	Spain
Xu, X et al	62	0	China
Fan et al	148	1	China
Zhang, B et al	82	82	China
Huang Y et al	36	36	China
Wan, S et al	135	1	China
Zhang, Y et al	115	1	China
Xu, Z et al	1	1	China
Arentz et al	21	11	China
Kujawski et al	12	0	China
Young et al	18	0	China
Sun et al	54		China
Pung et al	36	0	China
Qian et al	91	0	USA
Luo et al	183	7	USA
Zhou F et al	191	54	USA
Chen T et al	274	113	Singapore
Shi S et al	416	30	Singapore
Mao L et al	214	1	China
Ai JW et al	102	3	China
Liu Y et al	109	31	China
Shu L et al	545	0	China
Wei et al	100	3	China
Zhao W et al	77	5	China
Yang P et al	55	2	China
Qi D et al	267	4	China
Wen Y et al	417	3	China
Xu Y et al	45	0.09	China
Yan S et al	168	6	China
Wang L et al	18	0	China
Chen X et al	291	2	China
Liu S et al	620	0	China
Tian S et al	37	0	China
Lu H et al	265	1	China
Fu H et al	52	0	China

Pung et al	17	0	China
Dreher et al	50	7	China
Gritti et al	21	1	China
Spiteri et al	38	1	China
Covid-19 National Incident Room Surveillance Team Australia	295	3	China
Fan H et. al.	101	101	Italy
FernandezRuiz et. al.	17	5	Germany, Finland, Italy, Russia, Spain, France, Sweden, and Belgium
Han C et. al.	206	0	China
Hsih W-H et. al.	2	0	China
Huang WH et. al.	2	0	China
Kim ES et. al.	28	0	China
Liu Y et. al.	12	0	China
Pan F et. al.	21	0	Taiwan
Redd W et. al.	318	32	China
Ren L et. al.	5	1	China
Shi H et. al.	81	3	Korea
Song F et. al.	51	0	France
Wan Y et. al.	230	6	China
Wang L (b) et. al.	26	0	Europe
Wang L (c) et. al.	339	4	China

Wang X et. al.	1021	0	China
Wei X-S et. al.	84	0	China
Wu Y et. al.	74	1	China
Xiong Y et. al.	42	1	China
Yu P et. al.	4	1	China
Zhao X-Y et. al.	91	2	China
Total	10,427	749	

Supplementary figure S1 Forest plot depicting prevalence of diarrhea

Supplementary figure.2